{"id":35138,"date":"2025-08-20T15:19:16","date_gmt":"2025-08-20T13:19:16","guid":{"rendered":"https:\/\/ggba.swiss\/?p=35138"},"modified":"2025-08-20T15:25:49","modified_gmt":"2025-08-20T13:25:49","slug":"pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/","title":{"rendered":"Pilatus Biosciences launches first-in-human trial in collaboration with Roche"},"content":{"rendered":"\n

Pilatus Biosciences<\/a>, a biopharmaceutical company based at the Biop\u00f4le<\/a> in \u00c9palinges (Vaud), has announced the launch of its first-in-human Phase 1 trial. The study will test the company\u2019s lead candidate, PLT012, in combination with atezolizumab (Tecentriq), provided by Roche, in patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer.<\/p>\n\n\n\n

Founded in 2022 from research at the Ludwig Institute for Cancer Research<\/a> and supported by the Cancer Research Institute, Pilatus develops metabolic checkpoint immunotherapies designed to reprogram the tumor microenvironment (TME). Its international R&D activities are split between Switzerland and Taiwan, with a focus on liver and gastrointestinal cancers.<\/p>\n\n\n\n

Targeting the tumor microenvironment in liver cancer<\/h4>\n\n\n\n

PLT012 is a humanized monoclonal antibody designed to selectively block CD36-mediated lipid uptake, a mechanism that contributes to immune suppression and resistance to treatment in liver tumors. By targeting lipid metabolism, PLT012 seeks to convert \u201ccold\u201d tumors into more responsive ones, enhancing the effect of immune checkpoint inhibitors such as anti\u2013PD-L1 therapies.<\/p>\n\n\n\n

Preclinical studies have shown that PLT012 demonstrates potent activity as a monotherapy in liver cancer models, while also acting as a strong sensitizer when combined with checkpoint inhibitors. This dual activity suggests potential for both direct anti-tumor effects and improved responsiveness to existing therapies.<\/p>\n\n\n\n

\u201cThis collaboration represents an opportunity to investigate how modulation of the tumor microenvironment can enhance immune checkpoint blockade in liver cancer,\u201d said Dr. Ann-Lii Cheng, NTU Chair Professor and President Emeritus of the NTU Cancer Center at National Taiwan University, and a scientific collaborator with Pilatus. Dr. Cheng previously served as global principal investigator of the landmark IMbrave150 trial that established atezolizumab plus bevacizumab as a standard of care for HCC.<\/p>\n","protected":false},"excerpt":{"rendered":"

Vaud-based Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial for liver cancer.<\/p>\n","protected":false},"author":6,"featured_media":35146,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,890,886,901],"class_list":["post-35138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-healthcare","tag-rd","tag-technology-park"],"acf":[],"yoast_head":"\nPilatus Biosciences launches first-in-human trial | GGBa<\/title>\n<meta name=\"description\" content=\"Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pilatus Biosciences launches first-in-human trial | GGBa\" \/>\n<meta property=\"og:description\" content=\"Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T13:19:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T13:25:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Pilatus Biosciences launches first-in-human trial in collaboration with Roche\",\"datePublished\":\"2025-08-20T13:19:16+00:00\",\"dateModified\":\"2025-08-20T13:25:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\"},\"wordCount\":289,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"keywords\":[\"Biotech\",\"Healthcare\",\"R&D\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\",\"url\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\",\"name\":\"Pilatus Biosciences launches first-in-human trial | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"datePublished\":\"2025-08-20T13:19:16+00:00\",\"dateModified\":\"2025-08-20T13:25:49+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"The new clinical trial underscores Pilatus Biosciences\u2019 progress in advancing next-generation immunotherapies from preclinical research to early-stage clinical development. | \u00a9 Pilatus Biosciences\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pilatus Biosciences launches first-in-human trial in collaboration with Roche\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pilatus Biosciences launches first-in-human trial | GGBa","description":"Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/","og_locale":"en_US","og_type":"article","og_title":"Pilatus Biosciences launches first-in-human trial | GGBa","og_description":"Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial.","og_url":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-08-20T13:19:16+00:00","article_modified_time":"2025-08-20T13:25:49+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Pilatus Biosciences launches first-in-human trial in collaboration with Roche","datePublished":"2025-08-20T13:19:16+00:00","dateModified":"2025-08-20T13:25:49+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/"},"wordCount":289,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","keywords":["Biotech","Healthcare","R&D","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/","url":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/","name":"Pilatus Biosciences launches first-in-human trial | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","datePublished":"2025-08-20T13:19:16+00:00","dateModified":"2025-08-20T13:25:49+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche\u2019s atezolizumab in a Phase 1 trial.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Pilatus-bioscicences-1180x811-v2.jpeg","width":1180,"height":811,"caption":"The new clinical trial underscores Pilatus Biosciences\u2019 progress in advancing next-generation immunotherapies from preclinical research to early-stage clinical development. | \u00a9 Pilatus Biosciences"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-launches-first-in-human-trial-in-collaboration-with-roche\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Pilatus Biosciences launches first-in-human trial in collaboration with Roche"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/35138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=35138"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/35138\/revisions"}],"predecessor-version":[{"id":35142,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/35138\/revisions\/35142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/35146"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=35138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=35138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=35138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}